11:51 AM EST - Oncolytics Biotech Inc : Announced the initiation of a metastatic colorectal cancer Phase 2 study that will be referred to as REO 033. In this trial, second-line RAS-mutated, microsatellite-stable mCRC patients will be randomized to a control arm of bevacizumab (Avastin®) and fluorouracil, leucovorin, irinotecan or an experimental arm of pelareorep, bevacizumab, and FOLFIRI. The study is powered for statistical significance, with each study arm expected to enroll 30 patients. Oncolytics Biotech Inc
shares N.ONCY are trading -$0.08 at $1.04.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=4763987247780294
